ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

4-Methylmorpholine → tert-butyl N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-4-methylleucinate

HRID 254079
印刷

反応式

HRID 254079 の反応式
[F:1][C:2]1[CH:7]=[CH:6][C:5]([N:8]2[C:11](=[O:12])[C@H:10]([S:13][CH2:14][C:15]([C:17]3[CH:22]=[CH:21][C:20]([F:23])=[CH:19][CH:18]=3)=[O:16])[C@H:9]2[C:24]2[CH:38]=[CH:37][C:27]([O:28][CH2:29][C:30]([NH:32]CC(O)=O)=[O:31])=[CH:26][CH:25]=2)=[CH:4][CH:3]=1.CN1CC[O:43][CH2:42][CH2:41]1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.[CH3:68][C:69]([CH3:81])([CH3:80])[CH2:70][C@@H:71]([C:73]([O:75][C:76]([CH3:79])([CH3:78])[CH3:77])=[O:74])[NH2:72].OS([O-])(=O)=O.[K+]>C(Cl)Cl.O>[F:1][C:2]1[CH:3]=[CH:4][C:5]([N:8]2[C:11](=[O:12])[C@H:10]([S:13][CH2:14][C:15]([C:17]3[CH:18]=[CH:19][C:20]([F:23])=[CH:21][CH:22]=3)=[O:16])[C@H:9]2[C:24]2[CH:38]=[CH:37][C:27]([O:28][CH2:29][C:30]([NH:32][CH2:41][C:42]([NH:72][C@H:71]([C:73]([O:75][C:76]([CH3:79])([CH3:78])[CH3:77])=[O:74])[CH2:70][C:69]([CH3:81])([CH3:80])[CH3:68])=[O:43])=[O:31])=[CH:26][CH:25]=2)=[CH:6][CH:7]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

8

反応物 5

HCID 79724-MethylmorpholineHCID 516920Potassium bisulfateHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 54211560tert-Butyl (S)-2-amino-4,4-dimethylpentanoate2 回HCID 66842760N-{[4-((2R,3R)-1-(4-Fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio)-4-oxoazetidin-2-yl)phenoxy]acetyl}glycine

生成物 1

HCID 66842980tert-butyl N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-4-methylleucinate

試薬・触媒・溶媒 2

HCID 962Water溶媒HCID 6344Dichloromethane溶媒

実験手順

N-{[4-((2R,3R)-1-(4-Fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycine (20 mg, 0.037 mmol) was dissolved in 3 ml DCM. N-Methylmorpholine (9 μl, 0.082 mmol) and TBTU (14 mg, 0.044 mmol) were added. After 5 minutes, tert-butyl 4-methylleucinate (9 mg, 0.045 mmol) was added and the mixture was stirred for 2 h. Additional tert-butyl 4-methylleucinate (ca 3 mg, 0.015 mmol) was added. After 15 min, water (2 ml) was added and the mixture was acidified to a pH of 2 using 2M KHSO4. The aqueous phase was extracted with 2 ml DCM and the combined organic phases were washed with 3 ml water, dried over Na2SO4 and filtered. Removal of the solvent under reduced pressure gave the title compound. M/z: 724.

後処理

  1. waitAfter 15 min
  2. extractionThe aqueous phase was extracted with 2 ml DCM
  3. washthe combined organic phases were washed with 3 ml water
  4. dry with materialdried over Na2SO4
  5. filtrationfiltered
  6. customRemoval of the solvent under reduced pressure

出典と根拠

ORDレコード
ord-de50dcb8c6a147c296868fc7b1bb5949
出典データセット
uspto-grants-2011_01
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07871998B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート